Chemoprevention of Hepatocellular Carcinoma

Chemoprevention of hepatocellular carcinoma (HCC) refers to the use of medications, vaccines, or supplements to prevent or delay the development of HCC, particularly in individuals at high risk due to chronic liver disease (CLD). This concept was introduced over 50 years ago and remains a critical strategy for addressing HCC, given its long latency period and the global burden of the disease.

Key Drivers of HCC

HCC is primarily driven by:

1. Chronic Viral Hepatitis: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are leading causes of HCC worldwide.

2. Alcohol Use: Chronic alcohol consumption contributes to liver cirrhosis and HCC development.

3. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD/MASH): Previously known as non-alcoholic fatty liver disease (NAFLD/NASH), metabolic dysfunction is becoming an increasingly significant contributor to HCC due to the global rise in obesity and diabetes.

Chemopreventive Strategies

1. HBV Vaccination:

• Universal HBV vaccination is the most successful example of chemoprevention, reducing HBV-related HCC by 80–90% among children and young adults.
• HBV vaccination is considered the first true "anti-cancer vaccine."

2. Antiviral Therapies:

• HBV: Nucleos(t)ide analogues such as entecavir, tenofovir, and lamivudine, as well as interferon therapy, significantly reduce HCC risk in HBV patients, with hazard ratios around 0.5.
• HCV: Direct-acting antivirals (DAAs) for HCV have revolutionized treatment, reducing HCC incidence by 70–80% through viral eradication, which is the most effective chemopreventive strategy.

3. Aspirin:

• Observational studies show aspirin use is associated with a 24–41% reduced risk of HCC, likely due to its anti-inflammatory effects and COX-2 inhibition.
• However, the risk of bleeding limits its universal application for HCC prevention.

4. Non-Aspirin NSAIDs:

• Non-aspirin NSAIDs and COX-2 inhibitors, such as meloxicam, have shown inconsistent or minimal HCC risk reduction in clinical trials, making them less promising for chemoprevention.

5. Statins:

• Statins are consistently associated with a 30–50% lower HCC incidence across HBV, HCV, and MASLD patients.
• Lipophilic statins (e.g., simvastatin, atorvastatin) appear more effective than hydrophilic statins due to their greater hepatic and systemic action.

6. Metformin:

• Metformin shows a 40–50% reduction in HCC risk among patients with type 2 diabetes, although results vary when adjusted for concurrent use of statins or aspirin.
• Current guidelines do not recommend metformin solely for HCC prevention.

7. New Antidiabetic Drugs:

• GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin) show promise in reducing steatosis and potentially HCC risk in MASH models, although clinical validation is required.
• Thiazolidinediones (TZDs) and DPP4 inhibitors may reduce liver inflammation and fibrosis, but evidence for HCC prevention remains weak and inconsistent.

8. Antihypertensive Drugs:

• ACE inhibitors, ARBs, and beta-blockers may have anti-fibrotic or anti-angiogenic effects, but current human data do not support their use specifically for HCC chemoprevention.
• Non-selective beta-blockers like nadolol and carvedilol show potential HCC risk reduction in cirrhotic patients, while propranolol has not demonstrated clear benefit.

9. Targeted Agents:

• Erlotinib (EGFR inhibitor) and mTOR inhibitors (sirolimus, everolimus) show HCC-preventive potential in preclinical models, but clinical trial validation in non-cancer populations is lacking.

10. Dietary and Lifestyle Modifications:

• Coffee Consumption: Drinking more than two cups of coffee per day is associated with a 35–40% lower HCC risk due to its anti-inflammatory and antioxidant properties.
• Mediterranean Diet: Foods such as fish, white meat, fiber, and olive oil show protective associations.
• Vitamin and Supplementation: Vitamins D and E, branched-chain amino acids, and selenium supplementation may reduce HCC risk in deficient populations, but applicability is limited.

Guidelines and Recommendations

The American Association for the Study of Liver Diseases (AASLD) provides the following recommendations for HCC prevention:

• Encouraged: Antiviral therapy for HBV and HCV, coffee consumption, and metabolic control.
• Discouraged: Routine use of aspirin, metformin, or statins solely for chemoprevention due to insufficient evidence or associated risks.

Conclusion

The most effective strategies for HCC chemoprevention are controlling viral hepatitis through vaccination and antiviral therapies and implementing lifestyle modifications, including coffee consumption and metabolic control. While drugs like statins, aspirin, and GLP-1 receptor agonists show promise, further large-scale clinical validation is needed.